Janux CMO Departs, Company Assures No Change to Development Plans
JANX sits 22% above its 52-week low of $12.12.
Summary
Janux Therapeutics announced the departure of its Chief Medical Officer, William Go, effective June 23, 2026. This news follows an 8-K filing on the same day. While the departure of a CMO is a significant event for a biotech company, Janux stated it was a termination without cause, not due to disagreements, and that clinical development plans and timelines remain unchanged. The company has initiated a search for a successor.
At the time of this announcement, JANX was trading at $14.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $909.3M. The 52-week trading range was $12.12 to $35.34. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.